← Eichor
Study identifier: NCT06120166 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Condition: Diffuse Large B-cell Lymphoma  ·  Sponsor: He Huang

PhaseEARLY_Phase 1
Planned participants18
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma

This description comes directly from the study's public registry record.

Talk to the study team

Mingming Zhang  ·  86-13656674208  ·  mingmingzhang@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

The first affiliated hospital of medical college of zhejiang universityHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06120166